



---

**CONTROLLED SUBSTANCES BOARD  
VIRTUAL/TELECONFERENCE  
Virtual, 4822 Madison Yards Way, Madison  
Contact: Adam Barr (608) 266-2112  
January 14, 2022**

*The following agenda describes the issues that the Board plans to consider at the meeting. At the time of the meeting, items may be removed from the agenda. Please consult the meeting minutes for a description of the actions and deliberations of the Board.*

**AGENDA**

**9:30 A.M.  
OR IMMEDIATELY FOLLOWING THE REFERRAL CRITERIA  
WORK GROUP MEETING**

**OPEN SESSION – CALL TO ORDER – ROLL CALL**

- A. Adoption of Agenda (1-3)**
- B. Approval of Minutes November 12, 2021 (4-5)**
- C. Reminders: Conflicts of Interests, Scheduling Concerns**
- D. Introductions, Announcements and Recognition**
  - 1) Introduction: Troy Alton, Dentistry Examining Board Representative
  - 2) Recognition: Herbert Kaske, Dentistry Examining Board Representative
  - 3) Recognition: Special Guests of the November 2021 Annual Law Enforcement Hearing
- E. Administrative Matters – Discussion and Consideration**
  - 1) Department, Staff, and Board Updates
  - 2) Annual Policy Review **(6-9)**
  - 3) Elections of Officers, Appointment of Liaison and Alternates, Delegation of Authorities **(10-13)**
  - 4) Board Members – Term Expiration Dates
    - a. Alton, Troy
    - b. Barman, Subhadeep – 5/1/2019
    - c. Bellay, Yvonne
    - d. Bloom, Alan – 5/1/2020
    - e. Englebert, Doug
    - f. Ferguson, Kris
    - g. Kallio, Peter
    - h. Koresch, Sandy
    - i. Weitekamp, John
- F. Administrative Rule Matters – Discussion and Consideration**

- 1) Final Rule Draft and Legislative Report – CSB 2.80, Relating to Scheduling Oliceridine **(14-23)**
- 2) Scope Statement – CSB 2.91, Relating to Scheduling 4,4' – Dimethylaminorex **(24-25)**
- 3) Pending and Possible Rulemaking Projects

**G. Prescription Drug Monitoring Program (PDMP) Update – Discussion and Consideration**

- 1) WI ePDMP Operations
  - a. Recent and Upcoming Releases **(26-28)**
  - b. Status of Grant Projects:
    1. FY 2020 Harold Rogers Prescription Drug Monitoring Program
    2. FY 2021 Harold Rogers Prescription Drug Monitoring Program
    3. Buprenorphine Exclusion Project
  - c. Interstate Data Sharing **(29-30)**
  - d. EHR Integration Status
- 2) WI ePDMP Outreach **(31)**

**H. COVID-19 – Discussion and Consideration**

**I. Board Member Reports – Discussion and Consideration**

- 1) Medical Examining Board
- 2) Dentistry Examining Board
- 3) Board of Nursing
- 4) Pharmacy Examining Board

**J. Liaison Reports**

**K. Report from the Referral Criteria Work Group – Discussion and Consideration**

**L. Deliberation on Special Use Authorizations – Discussion and Consideration**

**M. Discussion and Consideration of Items Received After Preparation of the Agenda**

- 1) Introductions, Announcements, and Recognition
- 2) Administrative Matters
- 3) Election of Officers
- 4) Appointment of Liaisons and Alternates
- 5) Delegation of Authorities
- 6) Informational Items
- 7) Division of Legal Services and Compliance (DLSC) Matters
- 8) Education and Examination Matters
- 9) Credentialing Matters
- 10) Practice Matters
- 11) Legislative and Administrative Rule Matters
- 12) Liaison Reports
- 13) Appearances from Requests Received or Renewed
- 14) Speaking Engagements, Travel, or Public Relations Requests, and Reports
- 15) Consulting with Legal Counsel

**N. Public Comments**

**CONVENE TO CLOSED SESSION to deliberate on cases following hearing (s. 19.85(1)(a), Stats.); to consider licensure or certification of individuals (s. 19.85(1)(b), Stats.); to consider individual histories or disciplinary data (s. 19.85(1)(f), Stats.); and to confer with legal counsel (s. 19.85(1)(g), Stats.).**

- O.** Deliberation on Special Use Authorizations – Discussion and Consideration
- P.** Consulting with Legal Counsel

**RECONVENE TO OPEN SESSION IMMEDIATELY FOLLOWING CLOSED SESSION**

- Q.** Vote on Items Considered or Deliberated Upon in Closed Session if Voting is Appropriate
- R.** Open Session Items Noticed Above Not Completed in the Initial Open Session

**ADJOURNMENT**

**NEXT MEETING: MARCH 11, 2022**

\*\*\*\*\*  
MEETINGS AND HEARINGS ARE OPEN TO THE PUBLIC, AND MAY BE CANCELLED WITHOUT NOTICE.

Times listed for meeting items are approximate and depend on the length of discussion and voting. All meetings are held at 4822 Madison Yards Way, Madison, Wisconsin, unless otherwise noted. To confirm a meeting or to request a complete copy of the board's agenda, please call the listed contact person. The board may also consider materials or items filed after the transmission of this notice. Times listed for the commencement of disciplinary hearings may be changed by the examiner for the convenience of the parties. Requests for interpreters for the deaf or hard of hearing, or other accommodations, are considered upon request by contacting the Affirmative Action Officer, 608-266-2112, or the Meeting Staff at 608-266-5439.

**VIRTUAL/TELECONFERENCE  
CONTROLLED SUBSTANCES BOARD  
MEETING MINUTES  
NOVEMBER 12, 2021**

**PRESENT:** Subhadeep Barman, Yvonne Bellay, Alan Bloom, Doug Englebert, Sandy Koresch, John Weitekamp

**EXCUSED:** Kris Ferguson, Herbert Kaske, Peter Kallio

**STAFF:** Adam Barr, Executive Director; Jameson Whitney, Legal Counsel; Nilajah Hardin, Administrative Rules Coordinator; Kimberly Wood, Program Assistant Supervisor-Adv.; Katlin Schwartz, Bureau Assistant; and other DSPS Staff

**CALL TO ORDER**

Doug Englebert, Chairperson, called the meeting to order at 9:34 a.m. A quorum was confirmed with six (6) members present.

**ADOPTION OF AGENDA**

**MOTION:** Alan Bloom moved, seconded by Yvonne Bellay, to adopt the Agenda as published. Motion carried unanimously.

**APPROVAL OF MINUTES OF SEPTEMBER 10, 2021**

**MOTION:** Alan Bloom moved, seconded by Yvonne Bellay, to adopt the Minutes of September 10, 2021 as published. Motion carried unanimously.

**REVISED GUIDANCE REGARDING THE DESIGNATION OF  
GABAPENTIN AS A MONITORED PRESCRIPTION DRUG**

**MOTION:** John Weitekamp moved, seconded by Subhadeep Barman, to approve the updated Gabapentin guidance document as presented at the meeting for posting on the DSPS website. Motion carried unanimously.

**ADMINISTRATIVE RULE MATTERS**

**Preliminary Rule Draft**

***CSB 2.78, Relating to Scheduling Crotonyl Fentanyl***

**MOTION:** Subhadeep Barman moved, seconded by Sandy Koresch, to approve the preliminary rule draft of CSB 2.78, relating to scheduling Crotonyl Fentanyl, for posting for economic impact comments and submission to the Clearinghouse. Motion carried unanimously.

***CSB 2.79, Relating to Scheduling Remimazolam***

**MOTION:** Subhadeep Barman moved, seconded by Alan Bloom, to approve the preliminary rule draft of CSB 2.79, relating to scheduling Remimazolam, for posting for economic impact comments and submission to the Clearinghouse. Motion carried unanimously.

***CSB 2.81, Relating to Scheduling Brorphine***

**MOTION:** Subhadeep Barman moved, seconded by Sandy Koresch, to approve the preliminary rule draft of CSB 2.81, relating to scheduling Brorphine, for posting for economic impact comments and submission to the Clearinghouse. Motion carried unanimously.

**PRESCRIPTION DRUG MONITORING PROGRAM (PDMP) UPDATE**

**WI ePDMP Operations**

**FY 2020 Harold Rogers Prescription Drug Monitoring Program**

***Buprenorphine Naïve Alert***

**MOTION:** Subhadeep Barman moved, seconded by Alan Bloom, to accept the recommendation to implement Buprenorphine Naïve Alert for Buprenorphine prescribed for opioid use disorder within the past 5 years. Motion carried unanimously.

**REPORT FROM THE REFERRAL CRITERIA WORK GROUP**

**MOTION:** Subhadeep Barman moved, seconded by John Weitekamp, to accept the recommendation of the Referral Criteria Work Group and refer the specified providers to the appropriate examining boards for further proceedings. Motion carried unanimously.

**ADJOURNMENT**

**MOTION:** Alan Bloom moved, seconded by Subhadeep Barman, to adjourn the meeting. Motion carried unanimously.

The meeting adjourned at 11:04 a.m.

**State of Wisconsin  
Department of Safety & Professional Services**

**AGENDA REQUEST FORM**

<b>1) Name and title of person submitting the request:</b> Kimberly Wood, Program Assistant Supervisor-Adv. on behalf of Division of Policy Development Executive Directors		<b>2) Date when request submitted:</b> 12/13/2021 Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting	
<b>3) Name of Board, Committee, Council, Sections:</b> All Boards			
<b>4) Meeting Date:</b> First Meeting of 2022	<b>5) Attachments:</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	<b>6) How should the item be titled on the agenda page?</b> Annual Policy Review	
<b>7) Place Item in:</b> <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session	<b>8) Is an appearance before the Board being scheduled?</b> <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<b>9) Name of Case Advisor(s), if applicable:</b> N/A	
<b>10) Describe the issue and action that should be addressed:</b> Please be advised of the following Annual Policy Review items: <ol style="list-style-type: none"> <li>1. <b>Attendance/Quorum:</b> Thank you for your service and for your commitment to meeting attendance. If you cannot attend a meeting or if you have scheduling conflicts impacting your attendance, please let us know ASAP. Timely notification is appreciated as quorum is required for our Boards, Sections and Councils to meet pursuant to Open Meetings Law.</li> <li>2. <b>Walking Quorum:</b> Board/Section/Council members must not collectively discuss the body's business outside of a properly noticed meeting. Should several members of a body do so, the members could be violating the open meetings law.</li> <li>3. <b>Agenda Deadlines:</b> Please communicate agenda topics to your Executive Director before the agenda submission deadline which is at 12:00 pm, 8 business days prior to a meeting. (Attachment: Timeline of a Meeting)</li> <li>4. <b>Travel Voucher and Per Diem Submissions:</b> Please submit all Per Diem and Reimbursement claims to DSPS within 30 days of the close of each month in which expenses are incurred. (Attachments: Per Diem Example, Travel Voucher Example)</li> <li>5. <b>Lodging Accommodations/Hotel Cancellation Policy:</b> Lodging accommodations are available to eligible members. Standard eligibility: member must leave home before 6:00 a.m. to attend a meeting by the scheduled start time.                         <ul style="list-style-type: none"> <li>• If a member cannot attend a meeting it is their responsibility to cancel their reservation within the applicable cancellation timeframe. If a meeting is changed to occur remotely or is cancelled or rescheduled DSPS staff will cancel or modify reservations as appropriate.</li> </ul> </li> <li>6. <b>Inclement Weather Policy:</b> In the event of inclement weather the agency may change a meeting from an in-person venue to one that is executed remotely.</li> </ol>			
<b>11) Authorization</b>			
<b>Kimberly Wood</b>		<b>12/13/2021</b>	
Signature of person making this request		Date	
Supervisor (Only required for post agenda deadline items)		Date	
Executive Director signature (Indicates approval for post agenda deadline items)		Date	
<b>Directions for including supporting documents:</b> <ol style="list-style-type: none"> <li>1. This form should be saved with any other documents submitted to the <a href="#">Agenda Items</a> folders.</li> <li>2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director.</li> <li>3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.</li> </ol>			

## Timeline of a Meeting

---

**8 business days prior to the meeting:** All agenda materials are due to the Department by 12:00 pm, 8 business days prior to the meeting date.

**7 business days prior to the meeting:** The draft agenda page is due to the Executive Director. The Executive Director transmits to the Chair for review and approval.

**5 business days prior to the meeting:** The approved agenda is returned to the Bureau Assistant for agenda packet production and compilation.

**4 business days prior to the meeting:** Agenda packets are posted on the DSPS Board SharePoint site and on the Department website.

### Agenda Item Examples:

- Approval of the Agenda and Minutes (from the last meeting)
- Open Session Items
  - Public Hearings (on Admin Rules)
  - Administrative Matters
  - Legislation and Policy Matters
  - Administrative Rules Matters
  - Credentialing Matters
  - Education and Exam Issues
  - Public Agenda Requests
  - Current Issues Affecting the Profession
  - Public Comments
- Closed Session items
  - Deliberations on Proposed Disciplinary Actions
    - Stipulations
    - Administrative Warnings
    - Case Closings
    - Monitoring Matters
    - Professional Assistance Procedure (PAP) Issues
  - Proposed Final Decisions and Orders
  - Orders Fixing Costs/Matters Relating to Costs
  - Credentialing Matters
  - Education and Exam Issues

**Thursday of the Week Prior to the Meeting:** Agendas are published for public notice on the Public Notices and Meeting Minutes website: [publicmeetings.wi.gov](http://publicmeetings.wi.gov).

**1 business day after the Meeting:** "Action" lists are distributed by staff detailing board actions on closed session business.

**5 business days after the Meeting:** "To Do" lists are distributed to staff to ensure that board decisions are acted on and/or implemented within the appropriate divisions in the Department. Minutes approved by the board are published on the Department's website.

# Department of Safety and Professional Services

## PER DIEM REPORT

**INSTRUCTIONS:** Claimant records board-related activities by entering the date of an activity, the duration of time spent in that activity, the relevant purpose code (see purpose code descriptions below), where the activity is conducted, and the type of activity performed. Only one (1) \$25.00 per diem payment can be issued on any given calendar day.

**Purpose Codes:**

- A. Official meetings including video/teleconference calls** (automatic day of per diem): i.e., board, committee, board training or screening panels; **Hearings**, i.e., Senate Confirmation, legislative, disciplinary or informal settlement conferences; **Examinations and Test Development Sessions**, i.e., test administration, test review or analysis events, national testing events, tour of test facilities, etc.)
- B. Other** (One (1) per diem will be issued for every five (5) hours spent in category B, per calendar month): i.e., review of disciplinary cases, consultation on cases, review of meeting materials, board liaison work e.g., contacts regarding Monitoring, Professional Assistance Procedure, Credentialing, Education and Examinations

NAME OF EXAMINING BOARD OR COUNCIL			BOARD OR COUNCIL MEMBER'S NAME	
<b>EXAMPLE EXAMINING BOARD</b>			<b>MARY SUNSHINE</b>	
Activity Date	Duration of Activity	Purpose Code	Where Performed	Activity
MM/DD/YY	Hours/Minutes	A or B	City/Location (Home, Work, DSPS)	Describe Activity Performed (see purpose codes)
12/2/20	2 hrs	B	Pleasant Prairie/Home	Review of screening panel materials
12/3/20	2 hr / 30 mins	B	Pleasant Prairie/Home	Review of screening panel materials
12/10/20	1 hr	A	Pleasant Prairie/Home	Screening Panel Meeting - Teleconference
12/12/20	1 hr / 30 mins	B	Pleasant Prairie/Home	Case consultation
12/13/20	1 hr	B	Pleasant Prairie/Home	Liaison: Application Review
12/16/20	6 hrs	A	Madison/DSPS	Board Member Training
				<p><b>The 5-hour rule applies to "B" code activities. Add the 'B' codes within the calendar month and then divide by five (5) hours to calculate your per diem payment. In this case the total is seven (7) hours which equals one (1) day of per diem.</b></p> <p><b>Each 'A' code is an automatic day of per diem regardless of time spent in that activity. Ms. Sunshine is eligible for two (2) additional days of payment.</b></p> <p><b>Department staff completes the fields titled "Total Days Claimed".</b></p>
<b>CLAIMANT'S CERTIFICATION</b>			Comments:	
The undersigned certifies, in accordance with § 16.53, Wis. Stats., that this account for per diem, is just and correct; and that this claim is for service necessarily incurred in the performance of duties required by the State, as authorized by law.				
<i>Mary Sunshine</i>		<i>1/4/2021</i>		
Claimant's Signature	Date	Supervisor	Date	

EMPL ID: 100012345-0

To be completed by Department staff: **TOTAL DAYS CLAIMED: 3 @ \$25.00 = 75.00**



<b>Safety &amp; Professional Services</b>																
Department/ Division		<u>Example Examining Board</u>			Emp ID		100012345			Z						
State Officer/Employee Name		<u>Mary Sunshine</u>			Address		2424 Happy Road									
Mo/Yr		From/To:			City		Pleasant Prairie		State		WI		Zip-Code		53158	
FY	FUND	BUSINESS UNIT	DEPART	APPR CLASS	OBJECT	PROJECT				BALANCE SHEET ACCT	REPORTING CATEGORY	PROJECT NUMBER	AMOUNT			
													DEBIT	CREDIT		
2021	10000	16500	1651300200	12100	7340000	16500P1<BRD ID>										
				12800		16500P2<TRD ID>										
				22100												
												<b>TOTALS</b>				

Official Business		Travel Points		HDQS-TIME		Personal Vehicle	Meals, including tips			Other Allowable Expenses		Total Allowable Expenses		
Date	Purpose of Trip	From	To	Depart	Return	Miles	Lodging	Morning	Noon	Evening	Item	Amount	Taxable	Non-Taxable
Use	Board Meeting	Home base	Madison	Report times you left		Miles	P-card	\$8.00	\$10.00	\$20.00			Report	Report
separate		Madison	Home base	and returned home if		must be		Maximum in-state amounts					meal cost	meal cost
lines for	You must identify			meals are claimed		split.	Enter		or				here if there	here if there
each leg	the purpose of					Cannot	"P-card"	\$10.00	\$15.00	\$25.00			is <b>NO</b>	<b>IS</b> an
of your	your trip.					place	when hotel	Maximum out-of-state amounts					overnight	overnight
trip.						roundtrip	is provided						stay.	stay.
						total on	by DSPS	Must leave	Must leave	Must return				
						one line.		home	home	home after				
								before	before	7:00 p.m.				
								6:00 a.m.	10:30 a.m.					
									and return					
									home after					
									2:30 p.m.					
<b>LEGEND:</b>		Staff can fill in these areas.												
		Board Member <b>MUST</b> fill in these areas												

\*Item billed directly to the state agency

	<b>Sub-Totals</b>													
										<b>Mileage Costs</b>				
							<b>Miles at</b>	<b>0.510 cents/mile</b>			<b>Totals</b>			
										<b>Total Expenditure</b>				
										<b>Less Travel Advance</b>				
										<b>Net Amount Due</b>				

**Claimant's Statement § 16.53 Wisconsin Statutes**

I declare, under penalties, that all claimed travel expenses are true and correct and are in conformity with Wisconsin statute 16.53 and related agreements. This claim represents reasonable and actual expenses necessarily incurred by me personally in the performance of official duties and no portion was previously reimbursed to me by the State or any other source.

Date \_\_\_\_\_ Claimant's Signature \_\_\_\_\_

I certify that this travel claim is reasonable, proper, and in conformity with applicable statutes, travel schedule amounts, and/or collective bargaining agreements.

I certify that all expenses on this voucher conform to statutory, departmental or applicable collective bargaining provisions, and were necessary in the official performance of duties required by the State Expenditures are determined to be reasonable and proper, and that sufficient funds are available to pay this claim.

Agency Head or Authorized Representative \_\_\_\_\_

Date \_\_\_\_\_ Supervisor's Signature \_\_\_\_\_ Audited in accordance with S. 16.53 Wisconsin Statutes and allowed by the provisions of chapter 20.

**State of Wisconsin  
Department of Safety & Professional Services**

**AGENDA REQUEST FORM**

1) Name and title of person submitting the request: Katlin Schwartz, Bureau Assistant		2) Date when request submitted: 12/13/2021 Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting	
3) Name of Board, Committee, Council, Sections: Controlled Substances Board			
4) Meeting Date: 1/14/2022	5) Attachments: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	6) How should the item be titled on the agenda page? Administrative Matters <ul style="list-style-type: none"> <li>• Election of Officers, Appointment of Liaisons and Alternates, Delegation of Authorities</li> </ul>	
7) Place Item in: <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session	8) Is an appearance before the Board being scheduled? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	9) Name of Case Advisor(s), if applicable: N/A	
10) Describe the issue and action that should be addressed: <ol style="list-style-type: none"> <li>1) The Board, Council or Section should conduct Election Officers: Chairperson, Vice Chairperson &amp; Secretary</li> <li>2) The newly elected Chairperson should review and appoint/reappoint Liaisons and Alternates as appropriate</li> <li>3) The Board should review and then consider its existing delegated authorities including any modification of these delegations and any proposals for additional delegations.</li> </ol>			
11) <span style="float: right;">Authorization</span> <hr/> <div style="display: flex; justify-content: space-between;"> <span>Katlin Schwartz</span> <span>12/13/2021</span> </div> <hr/> <div style="display: flex; justify-content: space-between;"> <span>Signature of person making this request</span> <span>Date</span> </div> <hr/> <div style="display: flex; justify-content: space-between;"> <span>Supervisor (Only required for post agenda deadline items)</span> <span>Date</span> </div> <hr/> <div style="display: flex; justify-content: space-between;"> <span>Executive Director signature (Indicates approval for post agenda deadline items)</span> <span>Date</span> </div>			
Directions for including supporting documents: <ol style="list-style-type: none"> <li>1. This form should be saved with any other documents submitted to the <a href="#">Agenda Items</a> folders.</li> <li>2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director.</li> <li>3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.</li> </ol>			

## CONTROLLED SUBSTANCES BOARD

### 2021 Elections and Liaison Appointments

ELECTION RESULTS	
<b>Chairperson</b>	Doug Englebert
<b>Vice Chairperson</b>	Alan Bloom
<b>Secretary</b>	Yvonne Bellay

### Appointment of Liaisons and Alternates

LIAISON APPOINTMENTS	
<b>Special Use Authorization (SUA) Liaison(s)</b>	Alan Bloom, Yvonne Bellay
<b>PDMP Liaison(s)</b>	Subhadeep Barman <i>Alternates:</i> Padmaja Doniparthi, John Weitekamp-Pharmacy Issues
<b>Legislative Liaison(s)</b>	Doug Englebert <i>Alternate:</i> Peter Kallio
<b>SCAODA Representative</b>	Subhadeep Barman
<b>Referral Criteria Workgroup</b>	Doug Englebert, Peter Kallio, John Weitekamp Subhadeep Barman

### Delegation of Authorities

#### *Document Signature Delegations*

**MOTION:** Alan Bloom moved, seconded by Yvonne Bellay, to delegate authority to the Chairperson (or in absence of the Chairperson, the highest-ranking officer or longest serving board member in that succession) to sign documents on behalf of the Board in order to carry out its duties. Motion carried unanimously.

**MOTION:** Peter Kallio moved, seconded by Yvonne Bellay, in order to carry out duties of the Board, the Chairperson (or in absence of the Chairperson, the highest-ranking officer or longest serving board member in that

succession) has the ability to delegate signature authority for purposes of facilitating the completion of assignments during or between meetings. The members of the Board hereby delegate to the Executive Director or DPD Division Administrator, the authority to sign on behalf of a board member as necessary. Motion carried unanimously.

***Delegated Authority for Urgent Matters***

**MOTION:** Barman moved, seconded by Bellay, that in order to facilitate the completion of urgent matters between meetings, the Board delegates its authority to the Chairperson (or, in the absence of the Chairperson, the highest-ranking officer or longest serving board member in that succession), to appoint liaisons to the Department to act in urgent matters. Motion carried unanimously.

***Special Use Authorization Liaison(s) Delegation***

**MOTION:** Peter Kallio moved, seconded by Subhadeep Barman, to authorize the SUA Liaison(s) to review and make approval decisions regarding SUA applications and approve required training or credentialing on behalf of the Board. Furthermore, the Board authorizes DSPS staff to sign SUA permits on behalf of the Board. Motion carried unanimously.

**MOTION:** Peter Kallio moved, seconded by John Weitekamp, to authorize the SUA Liaison(s) to make all decisions related to Special Use Authorizations. Motion carried unanimously.

***Delegation to Chief Legal Counsel Due to Loss of Quorum***

**MOTION:** John Weitekamp moved, seconded by Alan Bloom, to delegate the review of disciplinary cases to the Department's Chief Legal Counsel due to lack of/loss of quorum after two consecutive meetings. Motion carried unanimously.

***Legislative Liaison(s) Delegation***

**MOTION:** Peter Kallio moved, seconded by Yvonne Bellay, to delegate authority to the Legislative Liaison(s) to speak on behalf of the Board regarding legislative matters. Motion carried unanimously.


***SCAODA Representative Delegation***

**MOTION:** Yvonne Bellay moved, seconded by Alan Bloom, to authorize the SCAODA representative to vote on behalf of the Board at the State Council on Alcohol and Other Drug Abuse meetings. Motion carried unanimously.

***PDMP Liaison(s) Delegation***

**MOTION:** Peter Kallio moved, seconded by Yvonne Bellay, to authorize PDMP Liaison(s) to make individual decisions on behalf of the Board when waiting for a Board meeting would unreasonably delay the development, testing, deployment, or operation of the PDMP. The Board also grants the PDMP liaison the authority to suspend access to the PDMP pursuant to CSB § 4.09(3). Motion carried unanimously.

**State of Wisconsin  
Department of Safety & Professional Services  
AGENDA REQUEST FORM**

<b>1) Name and title of person submitting the request:</b>  Nilajah Hardin, Administrative Rules Coordinator		<b>2) Date when request submitted:</b> 01/03/22 Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting	
<b>3) Name of Board, Committee, Council, Sections:</b> Controlled Substances Board			
<b>4) Meeting Date:</b> 01/14/22	<b>5) Attachments:</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	<b>6) How should the item be titled on the agenda page?</b> Administrative Rule Matters – Discussion and Consideration 1. Final Rule Draft and Legislative Report - CSB 2.80, Relating to Scheduling Oliceridine 2. Scope Statement – CSB 2.91, Relating to Scheduling 4,4'-Dimethylaminorex 3. Pending or Possible Rulemaking Projects	
<b>7) Place Item in:</b> <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session	<b>8) Is an appearance before the Board being scheduled?</b> <i>(If yes, please complete <a href="#">Appearance Request</a> for Non-DSPS Staff)</i> <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<b>9) Name of Case Advisor(s), if required:</b> N/A	
<b>10) Describe the issue and action that should be addressed:</b> Attachments: Clearinghouse Report, Final Rule Draft, Legislative Report – CSB 2.80 Scope Statement – CSB 2.91 Rule Projects Chart  Copies of all current Board Rule Projects Can be Viewed Here: <a href="https://dsps.wi.gov/Pages/RulesStatutes/PendingRules.aspx">https://dsps.wi.gov/Pages/RulesStatutes/PendingRules.aspx</a>			
<b>11) Authorization</b>			
 Signature of person making this request		01/03/22 Date	
Supervisor (if required)		Date	
Executive Director signature (indicates approval to add post agenda deadline item to agenda)    Date			
<b>Directions for including supporting documents:</b> 1. This form should be attached to any documents submitted to the agenda. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.			



---

# Wisconsin Legislative Council

## RULES CLEARINGHOUSE

---

**Scott Grosz**  
Clearinghouse Director

**Anne Sappenfield**  
Legislative Council Director

**Margit Kelley**  
Clearinghouse Assistant Director

### CLEARINGHOUSE REPORT TO AGENCY

[THIS REPORT HAS BEEN PREPARED PURSUANT TO S. 227.15, STATS. THIS IS A REPORT ON A RULE AS ORIGINALLY PROPOSED BY THE AGENCY; THE REPORT MAY NOT REFLECT THE FINAL CONTENT OF THE RULE IN FINAL DRAFT FORM AS IT WILL BE SUBMITTED TO THE LEGISLATURE. THIS REPORT CONSTITUTES A REVIEW OF, BUT NOT APPROVAL OR DISAPPROVAL OF, THE SUBSTANTIVE CONTENT AND TECHNICAL ACCURACY OF THE RULE.]

#### CLEARINGHOUSE RULE **21-098**

AN ORDER to create CSB 2.80, relating to scheduling oliceridine.

Submitted by **CONTROLLED SUBSTANCES BOARD**

11-23-2021 RECEIVED BY LEGISLATIVE COUNCIL.

12-06-2021 REPORT SENT TO AGENCY.

MSK:SM

**LEGISLATIVE COUNCIL RULES CLEARINGHOUSE REPORT**

This rule has been reviewed by the Rules Clearinghouse. Based on that review, comments are reported as noted below:

1. STATUTORY AUTHORITY [s. 227.15 (2) (a)]

Comment Attached YES  NO

2. FORM, STYLE AND PLACEMENT IN ADMINISTRATIVE CODE [s. 227.15 (2) (c)]

Comment Attached YES  NO

3. CONFLICT WITH OR DUPLICATION OF EXISTING RULES [s. 227.15 (2) (d)]

Comment Attached YES  NO

4. ADEQUACY OF REFERENCES TO RELATED STATUTES, RULES AND FORMS  
[s. 227.15 (2) (e)]

Comment Attached YES  NO

5. CLARITY, GRAMMAR, PUNCTUATION AND USE OF PLAIN LANGUAGE [s. 227.15 (2) (f)]

Comment Attached YES  NO

6. POTENTIAL CONFLICTS WITH, AND COMPARABILITY TO, RELATED FEDERAL  
REGULATIONS [s. 227.15 (2) (g)]

Comment Attached YES  NO

7. COMPLIANCE WITH PERMIT ACTION DEADLINE REQUIREMENTS [s. 227.15 (2) (h)]

Comment Attached YES  NO



STATE OF WISCONSIN  
CONTROLLED SUBSTANCES BOARD

---

IN THE MATTER OF RULE-MAKING	:	PROPOSED ORDER OF THE
PROCEEDINGS BEFORE THE	:	CONTROLLED SUBSTANCES BOARD
CONTROLLED SUBSTANCES BOARD	:	ADOPTING RULES
	:	(CLEARINGHOUSE RULE 061-21)

---

PROPOSED ORDER

An order of the Controlled Substances Board to create CSB 2.80 relating to scheduling Oliceridine.

Analysis prepared by the Department of Safety and Professional Services.

---

ANALYSIS

**Statutes interpreted:** s. 961.16, Stats.

**Statutory authority:** s. 961.11 (1) and (4), Stats.

**Explanation of agency authority:**

Section 961.11 (1), Stats. provides that “[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227.”

Section 961.11(4), Stats. provides that “[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30-day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2).”

**Related statute or rule:** s. 961.16, Stats.

**Summary of, and comparison with, existing or proposed federal regulation:**

On October 30, 2020, the Department of Justice, Drug Enforcement Administration published its interim final rule in the Federal Register listing Oliceridine into schedule II of the federal Controlled Substances Act. The scheduling action was effective October 30, 2020.

**Plain language analysis:**

This rule schedules Oliceridine as a Schedule II controlled substance.

The Controlled Substances Board did not receive an objection to similarly treat Oliceridine as a Schedule II controlled substance under ch. 961, Stats. within 30 days of the date of publication in the Federal Register of the final order designating Oliceridine as a controlled substance.

Pursuant to s. 961.11 (4), Stats., the Controlled Substances Board took affirmative action to similarly treat Oliceridine under ch. 961, Stats. by creating the following:

961.16 (3) (ta) Oliceridine.

The Affirmative Action order, dated December 7, 2020, took effect on December 14, 2020 to allow for publication in the Administrative Register and expires upon promulgation of a final rule.

**Summary of public comments received on statement of scope and a description of how and to what extent those comments and feedback were taken into account in drafting the proposed rule:** N/A

**Comparison with rules in adjacent states:**

**Illinois:** Illinois has not scheduled Oliceridine as a controlled substance.

**Iowa:** Iowa has not scheduled Oliceridine as a controlled substance.

**Michigan:** Michigan has not scheduled Oliceridine as a controlled substance.

**Minnesota:** Minnesota has not scheduled Oliceridine as a controlled substance.

**Summary of factual data and analytical methodologies:**

The methodology was to schedule Oliceridine to conform with the federal Controlled Substances Act.

**Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:**

The proposed rule was posted for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals. No comments were received.

**Fiscal Estimate:**

The Fiscal Estimate and Economic Impact Analysis are attached.

**Effect on small business:**

These proposed rules do not have an economic impact on small businesses, as defined in s. 227.114 (1), Stats. The Department’s Regulatory Review Coordinator may be contacted by email at Daniel.Hereth@wisconsin.gov, or by calling (608) 267-2435.

**Agency contact person:**

Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, P.O. Box 8366, Madison, Wisconsin 53708; telephone 608-267-7139; email at DSPSAdminRules@wisconsin.gov.

**Place where comments are to be submitted and deadline for submission:**

Comments may be submitted to Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, Madison, WI 53708-8366, or by email to DSPSAdminRules@wisconsin.gov. Comments must be received by January 14, 2022 to be included in the record of rulemaking proceedings.

-----  
TEXT OF RULE

SECTION 1. CSB 2.80 is created to read:

**CSB 2.80 Scheduling of Oliceridine.** Section 961.16 (3) (ta), Stats., is created to read:

961.16 (3) (ta) Oliceridine.

SECTION 2. EFFECTIVE DATE. The rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats.

-----  
(END OF TEXT OF RULE)  
-----

This Proposed Order of the Controlled Substances Board is approved for submission to the Governor and Legislature.

Dated \_\_\_\_\_

Agency \_\_\_\_\_

Chairperson  
Controlled Substances Board

## ADMINISTRATIVE RULES Fiscal Estimate & Economic Impact Analysis

<p>1. Type of Estimate and Analysis <input checked="" type="checkbox"/> Original   <input type="checkbox"/> Updated   <input type="checkbox"/> Corrected</p>	<p>2. Date November 19, 2021</p>
<p>3. Administrative Rule Chapter, Title and Number (and Clearinghouse Number if applicable) CSB 2.80</p>	
<p>4. Subject Scheduling Oliceridine</p>	
<p>5. Fund Sources Affected <input type="checkbox"/> GPR   <input type="checkbox"/> FED   <input type="checkbox"/> PRO   <input type="checkbox"/> PRS   <input type="checkbox"/> SEG   <input type="checkbox"/> SEG-S</p>	<p>6. Chapter 20, Stats. Appropriations Affected</p>
<p>7. Fiscal Effect of Implementing the Rule <input checked="" type="checkbox"/> No Fiscal Effect   <input type="checkbox"/> Increase Existing Revenues   <input type="checkbox"/> Increase Costs   <input type="checkbox"/> Decrease Costs <input type="checkbox"/> Indeterminate   <input type="checkbox"/> Decrease Existing Revenues   <input type="checkbox"/> Could Absorb Within Agency's Budget</p>	
<p>8. The Rule Will Impact the Following (Check All That Apply) <input type="checkbox"/> State's Economy   <input type="checkbox"/> Specific Businesses/Sectors <input type="checkbox"/> Local Government Units   <input type="checkbox"/> Public Utility Rate Payers <input type="checkbox"/> Small Businesses <b>(if checked, complete Attachment A)</b></p>	
<p>9. Estimate of Implementation and Compliance to Businesses, Local Governmental Units and Individuals, per s. 227.137(3)(b)(1). \$0</p>	
<p>10. Would Implementation and Compliance Costs Businesses, Local Governmental Units and Individuals Be \$10 Million or more Over Any 2-year Period, per s. 227.137(3)(b)(2)? <input type="checkbox"/> Yes   <input checked="" type="checkbox"/> No</p>	
<p>11. Policy Problem Addressed by the Rule On October 30, 2020, the Department of Justice, Drug Enforcement Administration published its interim final rule in the Federal Register listing oliceridine into schedule II of the federal Controlled Substances Act.</p>	
<p>12. Summary of the Businesses, Business Sectors, Associations Representing Business, Local Governmental Units, and Individuals that may be Affected by the Proposed Rule that were Contacted for Comments. The rule was posted on the Department's website for 14 days to solicit economic impact comments from businesses, business sectors, associations representing business, local governmental units, and individuals. No comments were received.</p>	
<p>13. Identify the Local Governmental Units that Participated in the Development of this EIA. None.</p>	
<p>14. Summary of Rule's Economic and Fiscal Impact on Specific Businesses, Business Sectors, Public Utility Rate Payers, Local Governmental Units and the State's Economy as a Whole (Include Implementation and Compliance Costs Expected to be Incurred) None.</p>	
<p>15. Benefits of Implementing the Rule and Alternative(s) to Implementing the Rule The benefit is that the federal and state controlled substances acts will be uniform to avoid confusion. In addition, it is in the best interest of Wisconsin citizens to schedule Oliceridine as a controlled substance.</p>	
<p>16. Long Range Implications of Implementing the Rule The long range implication of implementing the rule will be to schedule Oliceridine as a schedule II controlled substance.</p>	
<p>17. Compare With Approaches Being Used by Federal Government The federal government has scheduled Oliceridine as a schedule II controlled substance.</p>	
<p>18. Compare With Approaches Being Used by Neighboring States (Illinois, Iowa, Michigan and Minnesota) Illinois: Illinois has not scheduled oliceridine as a controlled substance.</p>	

**ADMINISTRATIVE RULES**  
**Fiscal Estimate & Economic Impact Analysis**

Iowa: Iowa has not scheduled oliceridine as a controlled substance.

Michigan: Michigan has not scheduled oliceridine as a controlled substance.

Minnesota: Minnesota has not scheduled oliceridine as a controlled substance.

---

19. Contact Name	20. Contact Phone Number
Nilajah Hardin, Administrative Rules Coordinator	608-267-7139

---

This document can be made available in alternate formats to individuals with disabilities upon request.

**ADMINISTRATIVE RULES**  
**Fiscal Estimate & Economic Impact Analysis**

**ATTACHMENT A**

---

1. Summary of Rule's Economic and Fiscal Impact on Small Businesses (Separately for each Small Business Sector, Include Implementation and Compliance Costs Expected to be Incurred)

---

2. Summary of the data sources used to measure the Rule's impact on Small Businesses

---

3. Did the agency consider the following methods to reduce the impact of the Rule on Small Businesses?

- Less Stringent Compliance or Reporting Requirements
  - Less Stringent Schedules or Deadlines for Compliance or Reporting
  - Consolidation or Simplification of Reporting Requirements
  - Establishment of performance standards in lieu of Design or Operational Standards
  - Exemption of Small Businesses from some or all requirements
  - Other, describe:
- 

4. Describe the methods incorporated into the Rule that will reduce its impact on Small Businesses

---

5. Describe the Rule's Enforcement Provisions

---

6. Did the Agency prepare a Cost Benefit Analysis (if Yes, attach to form)

- Yes    No
-

**STATE OF WISCONSIN  
CONTROLLED SUBSTANCES BOARD**

---

**IN THE MATTER OF RULEMAKING :  
PROCEEDINGS BEFORE THE : REPORT TO THE LEGISLATURE  
CONTROLLED SUBSTANCES BOARD : CR 061-21**

---

**I. THE PROPOSED RULE:**

The proposed rule, including the analysis and text, is attached.

**II. REFERENCE TO APPLICABLE FORMS: N/A**

**III. FISCAL ESTIMATE AND EIA:**

The Fiscal Estimate and EIA is attached.

**IV. DETAILED STATEMENT EXPLAINING THE BASIS AND PURPOSE OF THE PROPOSED RULE, INCLUDING HOW THE PROPOSED RULE ADVANCES RELEVANT STATUTORY GOALS OR PURPOSES:**

On October 30, 2020, the Department of Justice, Drug Enforcement Administration published its interim final rule in the Federal Register listing oliceridine into schedule II of the federal Controlled Substances Act. The scheduling action was effective October 30, 2020.

The Controlled Substances Board did not receive an objection to similarly treat oliceridine as a Schedule II controlled substance under ch. 961, Stats. within 30 days of the date of publication in the Federal Register of the final order designating oliceridine as a controlled substance.

This rule schedules oliceridine as a Schedule II controlled substance.

**V. SUMMARY OF PUBLIC COMMENTS AND THE BOARD'S RESPONSES, EXPLANATION OF MODIFICATIONS TO PROPOSED RULES PROMPTED BY PUBLIC COMMENTS:**

Per s. 961.11(4), Stats., if no objection is made, the board shall promulgate a final rule for which notice of proposed rulemaking is omitted. Therefore, the Board did not hold a public hearing.

**VI. RESPONSE TO LEGISLATIVE COUNCIL STAFF RECOMMENDATIONS:**

Legislative Council staff did not make any recommendations.

**VII. REPORT FROM THE SBRRB AND FINAL REGULATORY FLEXIBILITY ANALYSIS: N/A**

# STATEMENT OF SCOPE

## CONTROLLED SUBSTANCES BOARD

Rule No.: CBS 2.91

Relating to: Scheduling 4,4'-Dimethylaminorex

Rule Type: Permanent

1. Finding/nature of emergency (Emergency Rule only): N/A

2. Detailed description of the objective of the proposed rule:

The objective of the rule is to schedule 4,4'-Dimethylaminorex as a Schedule I controlled substance. The Controlled Substances Board determines the scheduling of 4,4'-Dimethylaminorex as a Schedule I controlled substance is in the best interest of the citizens of Wisconsin.

3. Description of the existing policies relevant to the rule, new policies proposed to be included in the rule, and an analysis of policy alternatives:

On August 12, 2021, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing 4,4'-Dimethylaminorex into schedule I of the federal Controlled Substances Act. The scheduling action is effective September 13, 2021. The Controlled Substances Board did not receive an objection to similarly listing 4,4'-Dimethylaminorex as a schedule I under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing 4,4'-Dimethylaminorex as a schedule I controlled substance.

Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats 4,4'-Dimethylaminorex under chapter 961, Stats. by creating the following:

**CSB 2.91 Addition of 4,4'-Dimethylaminorex to schedule I.** Section 961.14 (7) (cm), Stats., is created to read:

961.14 (7) (cm) *4,4'-Dimethylaminorex.*

The Affirmative Action order, dated September 16, 2021, took effect on September 27, 2021, when it was published in the Administrative Register and expires upon promulgation of a final rule.

4. Detailed explanation of statutory authority for the rule (including the statutory citation and language):

**961.11 (1)** The controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227.

**961.11(4)** If a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30-day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or



findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2).

**5. Estimate of amount of time that state employees will spend developing the rule and of other resources necessary to develop the rule:**

60 hours

**6. List with description of all entities that may be affected by the proposed rule:**

Law enforcement, district attorney offices, Dept of Justice, state courts, prescribers, pharmacists, pharmacies, and the Controlled Substances Board.

**7. Summary and preliminary comparison with any existing or proposed federal regulation that is intended to address the activities to be regulated by the proposed rule:**

On August 12, 2021, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing 4,4'-Dimethylaminorex into schedule I of the federal Controlled Substances Act. The scheduling action is effective September 13, 2021. The Controlled Substances Board did not receive an objection to similarly listing 4,4'-Dimethylaminorex as a schedule I under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing 4,4'-Dimethylaminorex as a schedule I controlled substance.

**8. Anticipated economic impact of implementing the rule (note if the rule is likely to have a significant economic impact on small businesses):**

The proposed rule will have minimal to no economic impact on small businesses and the state's economy as a whole.

**Contact Person:** Nilajah Hardin, Administrative Rules Coordinator, [DSPSAdminRules@wisconsin.gov](mailto:DSPSAdminRules@wisconsin.gov), (608) 267-7139.

Approved for publication:

Approved for implementation:

\_\_\_\_\_  
Authorized Signature

\_\_\_\_\_  
Authorized Signature

\_\_\_\_\_  
Date Approved

\_\_\_\_\_  
Date Approved

**State of Wisconsin  
Department of Safety & Professional Services**

**AGENDA REQUEST FORM**

<b>1) Name and title of person submitting the request:</b> Marjorie Liu <b>Program Lead, PDMP</b>		<b>2) Date when request submitted:</b> 1/4/2022 <small>Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting</small>	
<b>3) Name of Board, Committee, Council, Sections:</b> Controlled Substances Board			
<b>4) Meeting Date:</b> 1/14/2022	<b>5) Attachments:</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	<b>6) How should the item be titled on the agenda page?</b> Prescription Drug Monitoring Program (PDMP) Updates – Discussion and Consideration	
<b>7) Place Item in:</b> <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session	<b>8) Is an appearance before the Board being scheduled?</b> <i>(If yes, please complete <a href="#">Appearance Request</a> for Non-DSPS Staff)</i>  <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<b>9) Name of Case Advisor(s), if required:</b>	
<b>10) Describe the issue and action that should be addressed:</b> 1. WI ePDMP Operations <ul style="list-style-type: none"> <li>a. Recent and Upcoming Releases</li> <li>b. Status of Grant Projects:                         <ul style="list-style-type: none"> <li>i. FY 2020 Harold Rogers Prescription Drug Monitoring Program</li> <li>ii. FY 2021 Harold Rogers Prescription Drug Monitoring Program</li> <li>iii. Buprenorphine Exclusion Project</li> </ul> </li> <li>c. Interstate Data Sharing</li> <li>d. EHR Integration Status</li> </ul> 2. WI ePDMP Outreach			
<b>11) Authorization</b>			
Signature of person making this request		Date	
Supervisor (if required)		Date	
Executive Director signature (indicates approval to add post agenda deadline item to agenda)		Date	
<b>Directions for including supporting documents:</b> 1. This form should be attached to any documents submitted to the agenda. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.			

# 2020-2022 Development and Release Summary

Updated 01.04.2022

Release Date	Description
<b>Pending</b>	
<p><b>R26</b> Release date TBD</p>	<p>Buprenorphine Exclusion Project</p> <ul style="list-style-type: none"> <li>Ability to override prescriber facing alerts, metrics, and MME calculations for certain drugs.</li> </ul> <p>Maintenance Updates</p> <ul style="list-style-type: none"> <li>RxCheck 3.0 Upgrades</li> </ul>
<b>Completed</b>	
<p><b>HRG 2020 Component 1</b> Release date TBD</p>	<p>Security Enhancements</p> <ul style="list-style-type: none"> <li>Two-Factor Authentication</li> <li>Compromised Email Address Check</li> </ul> <p>Patient Report and other User Experience Updates</p>
<p><b>R25</b> November 2021</p>	<p>Maintenance Updates</p> <ul style="list-style-type: none"> <li>Adjustments to triggering Annual Terms and Conditions prompt</li> <li>Enhanced EHR Integration Testing capabilities</li> </ul> <p>Chatbot display changes</p>
<p><b>R24</b> August 2021</p>	<p>Text Updates</p> <ul style="list-style-type: none"> <li>Gabapentin related text changes to the Submitter Error Email.</li> </ul> <p>Security-Related Enhancements</p>
<p><b>R23</b> July 2021</p>	<p>Text Updates</p> <ul style="list-style-type: none"> <li>Gabapentin related text changes to the Submitter Error Email.</li> </ul>
<p><b>R22</b> July 2021</p>	<p>Pharmacy-Related Enhancements</p> <ul style="list-style-type: none"> <li>Missing DEA Number Error Process Updates</li> </ul> <p>Administrative-Related Enhancements</p>
<p><b>R21</b> May 2021</p>	<p>New Design Enhancements</p> <ul style="list-style-type: none"> <li>Proactive MC/HCP linkage renewals</li> <li>Search enhancements</li> </ul> <p>Administrative-Related Enhancements</p> <p>Additional administrator tools</p>
<p><b>R20</b> March 2021</p>	<p>WI DOJ-Medical College of Wisconsin DataShare Project</p> <ul style="list-style-type: none"> <li>Automatically send data extracts to DOJ-MCW</li> <li>Automatically receive data extracts from DOJ-MCW</li> </ul> <p>Administrative-Related Enhancements</p> <ul style="list-style-type: none"> <li>Additional improvements to query process</li> <li>Additional administrator tools</li> </ul>

<p style="text-align: center;"><b>R19</b> <b>September 2020</b></p>	<p>New Design Enhancements</p> <ul style="list-style-type: none"> <li>• Enhanced MME calculation process</li> <li>• Ability to set map display defaults</li> </ul> <p>Administrative-Related Enhancements</p> <ul style="list-style-type: none"> <li>• Improvements to query approval process</li> </ul> <p>Search Engine Optimization</p> <p>Updates to non-user facing parts of the PDMP to optimize search engine results</p>
<p style="text-align: center;"><b>R18</b> <b>July 2020</b></p>	<p>New Design Enhancements</p> <ul style="list-style-type: none"> <li>• Updated layout and design of Patient Report including alerts and dispensing details, based on user feedback</li> <li>• Opioid naïve alert</li> </ul> <p>Additional EHR Enhancements</p> <ul style="list-style-type: none"> <li>• Multi-state default settings</li> </ul> <p>Prescriber Metrics Notifications</p> <p>Proactive notice to prescribers to review metrics, based on time and/or prescribing thresholds</p>
<p style="text-align: center;"><b>R17.1</b> <b>April 2020</b></p>	<p>Pharmacy-Related Enhancements</p> <ul style="list-style-type: none"> <li>• Display of Date Sold, if provided in the submission</li> <li>• ASAP file processing improvements</li> </ul>
<p style="text-align: center;"><b>R17</b> <b>March 2020</b></p>	<p>Pharmacy-Related Enhancements</p> <ul style="list-style-type: none"> <li>• Improvements to workflow for error corrections/void</li> <li>• Display of Date Sold, if provided in the submission</li> </ul> <p>New Design Enhancements</p> <ul style="list-style-type: none"> <li>• Better access to history of recent Patient Reports for Delegates</li> <li>• Additional data element on overdose alerts entered by law enforcement to capture administration of Naloxone</li> <li>• MME calculator</li> </ul> <p>Additional EHR Enhancements</p> <ul style="list-style-type: none"> <li>• Expanded patient search from within EHR</li> <li>• Expanded navigation from within EHR</li> </ul>

## Interstate Data Sharing

RxCheck/EHR	PMPi
<b>In Progress</b>	
<b>MO</b>	
<b>Connected</b>	
IL, MD, NE, PA, UT, WA,	AZ, CO, DE, FL, HI, IA, ID, IN, KS, ME, MI, MN, MT, NC, ND, NM, NV, NY, PR, SC, SD, TN, WV, Military Health System

## WI ePDMP Integration Services Summary

*Current as of 1.4.2022*

Pending Health Systems and EHR Platforms
Advanced Pain Management (In Development)
Advent Health (In Development)
Advent Health - Cerner
Athena (In Discussion)
DrFirst (In Development)
Marshfield EHR System Change (In Discussion/Contracting)
Prairie Clinic (In Discussion)
Wisconsin Statewide Health Information Network (Converting to new EHR Platform)
M Health Fairview (In Development)
Bluestone Physician Services (In Discussion/Contracting)
Clean Slate (In Development)
Connected Health Systems (approx. 50% of monthly patient queries)
Ascension Wisconsin
Aspirus Health Care
Aurora Health Care
Children's Hospital of Wisconsin
Froedtert & the Medical College of Wisconsin
GHC of South Central Wisconsin
Gundersen Health System
HealthPartners
HSHS / Prevea Health

Marshfield Clinic
Mayo Clinic
Mercy Health
Monroe Clinic
NOVO Health Technology Group
ProHealth Care
SSM Health
Thedacare
UnityPoint
UW Health
Wisconsin Statewide Health Information Network

## 2022 WI PDMP Outreach Calendar

MONTH	EVENT	DESCRIPTION	DATES	NOTES
January	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	1/13, 4/14	Quarterly meeting
February				
March				
April	RxCheck Governance Board Annual Meeting	Participant; Annual meeting for state PDMP administrators	TBD	TBD
	Rx Drug Abuse & Heroin Summit	Participant; national conference led by multidisciplinary experts for stakeholders addressing the opioid crisis	4/18-4/21	Atlanta, GA
May				
June				
July				
August				
September				
October				
November				
December				